Gilead Sciences | GILD - Le Chiffre D'Affaires De Vente





Ventes Changement Date
AbbVie USD 16.99B 1.99B 2026-06
Agios Pharmaceuticals USD 44.74M 25.94M 2026-06
ALKERMES USD 496.01M 103.1M 2026-06
Alnylam Pharmaceuticals USD 1.29B 120M 2026-06
Amgen USD 10.1B 1.48B 2026-06
Biogen USD 2.74B 490M 2026-06
BioMarin Pharmaceutical USD 990M 224M 2026-06
Bristol-Myers Squibb USD 12.97B 1.48B 2026-06
Coherus Biosciences USD 12.75M 1.18M 2025-12
Eli Lilly USD 22.97B 3.17B 2026-06
Gilead Sciences USD 7.8B 800M 2026-06
GlaxoSmithKline GBP 8.41B 781M 2026-06
Glaxosmithkline GBP 10.09B 1.37B 2026-03
Incyte USD 1.67B 400M 2026-06
J&J USD 25.31B 1.21B 2026-06
Merck USD 16.6B 310M 2026-06
Moderna USD 100M 289M 2026-06
Neurocrine Biosciences USD 959M 148M 2026-06
Novartis USD 14.41B 1.3B 2026-06
Pfizer USD 15.03B 530M 2026-06
PTC Therapeutics USD 361M 88M 2026-06
Puma Biotechnology USD 80.54M 33.46M 2024-09
Regeneron Pharmaceuticals USD 4.29B 690M 2026-06
Sangamo BioSciences USD 356K 125K 2024-06
Sanofi EUR 11.95B 710M 2026-06
Sarepta Therapeutics USD 401.3M 329.5M 2026-06
United Therapeutics USD 783.3M 1.8M 2026-06
Vertex Pharmaceuticals USD 3.33B 340M 2026-06